New combo therapy aims to reduce radiation for lymphoma patients
NCT ID NCT03341520
First seen Apr 25, 2026 · Last updated May 24, 2026 · Updated 7 times
Summary
This study tested a new approach for people with early-stage follicular lymphoma, a slow-growing blood cancer. Instead of standard full-dose radiation, patients received a low dose of radiation along with the drug Obinutuzumab (Gazyvaro). The goal was to see if this combination could still control the cancer while reducing side effects from radiation. The trial involved 89 adults with untreated stage I or II disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STAGE II GRADE 1 FOLLICULAR LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Klinikum Kempten
Kempten, Germany
-
LMU
Munich, 81377, Germany
-
Site Marburg
Marburg, Germany
-
TU
Munich, 81675, Germany
-
University of Cologne
Cologne, 50924, Germany
-
University of Essen
Essen, 45122, Germany
-
University of Frankfurt
Frankfurt, 60590, Germany
-
University of Heidelberg
Heidelberg, 69120, Germany
-
University of Muenster
Münster, Germany
-
University of Tuebingen
Tübingen, Baden-Wurttemberg, Germany
-
University of Ulm
Ulm, 89081, Germany
-
Vivantes Klinikum
Berlin, Germany
Conditions
Explore the condition pages connected to this study.